Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Butaselen plus standard treatment in fibrosing interstitial lung disease (phase IIa)
ChiCTR2600122134Phase 2Completed
- Sponsor
- China-Japan Friendship Hospital
- Start
- Apr 2026
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BS1801 in pulmonary fibrosis (PF), Nonspecific Interstitial Pneumonia (NSIP), chronic hypersensitivity pneumonitis (cHP) and 2 more (3 arms), sponsored by China-Japan Friendship Hospital. Primary endpoints: Adverse events at Week12, Serious adverse events at Week12 and 1 more. Started Apr 2026; status: completed.
02
Drugs
BS1801
03
Conditions
pulmonary fibrosis (PF)Nonspecific Interstitial Pneumonia (NSIP)chronic hypersensitivity pneumonitis (cHP)Unclassifiable Idiopathic Interstitial PneumoniaInterstitial Pneumonia With Autoimmune Features (IPAF)
Beyond the preview
Go deeper on ChiCTR2600122134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122134.